Parker Waichman LLP is currently evaluating lawsuits on behalf of Proscar, Propecia, Avodart and Jalyn users who developed high grade prostate cancer that may be associated with the use of these medications.
New York, New York (PRWEB) March 20, 2012
Parker Waichman LLP, a national law firm dedicated to protecting the legal rights of victims of defective drug side effects, commends Health Canada's decision to add new warnings to the labels of finasteride (Proscar and Propecia) and dutasteride (Avodart and Jalyn) regarding their association with high grade prostate cancer, the most aggressive form of the disease. Parker Waichman LLP is currently evaluating lawsuits on behalf of Proscar, Propecia, Avodart and Jalyn users who developed high grade prostate cancer that may be associated with the use of these medications. [hc-sc.gc.ca/ahc-asc/media/advisories-avis/_2012/2012_38-eng.php]
Proscar (finasteride 5mg), Propecia (finasteride 1mg), Avodart (dutasteride) and Jalyn (dutasteride and tamsulosin) all belong to a class of drugs called 5-alpha reductase inhibitors, or 5-ARIs. Proscar, Avodart and Jalyn are all used to treat enlarged prostate, while Propecia is used to treat male pattern hair loss. Avodart and Proscar are also approved to reduce the risk of urinary retention or surgery related to an enlarged prostate. According to recent information from the U.S. Food & Drug Administration (FDA), almost 5 million men were prescribed one of these medications between 2002 and 2009. [fda.gov/Drugs/DrugSafety/ucm258314.htm]
According to a press release issued by Health Canada on March 20, 2012, finasteride and dutasteride may be associated with an increased risk of developing high-grade prostate cancer. High-grade prostate cancer is an aggressive type of prostate cancer that grows and spreads more quickly than low-grade prostate cancer. New warnings on this risk have been added to the Canadian drug labels for finasteride and dutasteride products, the agency said.
The new safety information is based on Health Canada's review of two large international clinical trials, the Prostate Cancer Prevention Trial (PCPT) and the Reduction by Dutasteride of Prostate Cancer Events (REDUCE) trial. According to Health Canada, the trials showed that the long-term daily use (over 4 years) of finasteride (5 mg) and dutasteride in men aged 50 years and older was associated with a small but statistically significant increased risk of high-grade prostate cancer. The 1 mg finasteride strength (Propecia) was not included in these trials but a potential risk has not been ruled out, according to Health Canada. [hc-sc.gc.ca/ahc-asc/media/advisories-avis/_2012/2012_38-eng.php]
Last year, the FDA's review of the same studies prompted the agency to add similar warnings to the labels of Proscar, Avodart, Jalyn and Propecia in the U.S. In June 2011, the agency issued a Drug Safety Communication notifying the public that the “Warnings and Precautions” sections of the labels of all FDA-approved 5-ARIs was being modified to include new information that they may increase the risk of high-grade prostate cancer. [fda.gov/Drugs/DrugSafety/ucm258314.htm]
Parker Waichman LLP is currently offering free legal consultations to victims of high-grade prostate cancer that may be associated with the use of Proscar, Propecia, Avodart or Jalyn. Please contact their office by visiting the firm’s 5-ARI side effects page at http://www.yourlawyer.com. Free case evaluations are also available by calling 1 800 LAW INFO (1-800-529-4636).
For more information regarding finasteride and dutasteride side effects lawsuits and Parker Waichman LLP, please visit: http://www.yourlawyer.com or call 1-800-LAW-INFO (1-800-529-4636).
Parker Waichman LLP
Herb Waichman, Partner